Sanjivani Paranteral Fair Value
Sanjivani Paranteral (SANJIVIN) average fair value is ₹43.18 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹129.3 (-66.6%), fair value range ₹8.77–₹104.0. Examine Sanjivani Paranteral quarterly financials for recent quarterly revenue, profit and EPS trends.
Fair Value Analysis Export
SANJIVIN Fair Value vs Current Price — Valuation Summary
SANJIVIN average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. See SANJIVIN price book multiple to compare market price against book value per share.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
SANJIVIN Fair Value Analysis — Data Sources & Coverage
Sanjivani Paranteral financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. For live price and a broader fundamental view, visit Sanjivani Paranteral share price chart.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
SANJIVIN vs Healthcare Sector Peers — P/E, P/B & Market Cap
Sanjivani Paranteral P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Sun Pharmaceutical | SUNPHARMA | 40.81 | 5.74 | ₹450,643 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.